WO2016080911A1 - Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés - Google Patents

Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés Download PDF

Info

Publication number
WO2016080911A1
WO2016080911A1 PCT/SG2015/050454 SG2015050454W WO2016080911A1 WO 2016080911 A1 WO2016080911 A1 WO 2016080911A1 SG 2015050454 W SG2015050454 W SG 2015050454W WO 2016080911 A1 WO2016080911 A1 WO 2016080911A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood glucose
server apparatus
wearable device
wearer
value
Prior art date
Application number
PCT/SG2015/050454
Other languages
English (en)
Inventor
Sunny SHARMA
Chirn Chye Boon
Jiafu LIN
Original Assignee
Nanyang Technological University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanyang Technological University filed Critical Nanyang Technological University
Priority to AU2015350582A priority Critical patent/AU2015350582A1/en
Priority to SG11201704055YA priority patent/SG11201704055YA/en
Priority to EP15860746.5A priority patent/EP3220824A4/fr
Priority to JP2017526639A priority patent/JP2017538474A/ja
Publication of WO2016080911A1 publication Critical patent/WO2016080911A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
    • A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
    • A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0531—Measuring skin impedance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A61B5/7267—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems involving training the classification device
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
    • A61B2562/16—Details of sensor housings or probes; Details of structural supports for sensors
    • A61B2562/164—Details of sensor housings or probes; Details of structural supports for sensors the sensor is mounted in or on a conformable substrate or carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
    • A61B5/6813—Specially adapted to be attached to a specific body part
    • A61B5/6825—Hand
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Definitions

  • the invention relates to a server apparatus for monitoring blood glucose in a wearer of a wearable device.
  • the invention also relates to a wearable device for blood glucose monitoring.
  • the invention also relates to a computing device for
  • the invention also relates to a method of operation of the server apparatus.
  • the invention also relates to a method of operation of the wearable device.
  • the invention also relates to a method of operation of the computing device.
  • the invention also relates to a computer program product and/or a computer program for implementing the methods.
  • the invention has particular, but not exclusive, application for ongoing - for example, continuous - non-invasive blood glucose monitoring for the wearer of the wearable device.
  • continuous may mean ongoing monitoring where data is gathered and/or transmitted for processing on a non-stop basis. Additionally or alternatively, this may mean data is gathered and/or transmitted for processing in batches at discrete intervals of, for example, between one and 15 minutes. Such time intervals may be specified by a clinician.
  • Implementation of the techniques disclosed herein may allow for accurate noninvasive self-blood glucose monitoring. Further, the techniques disclosed herein may allow for ongoing monitoring with minimal calibration.
  • Diabetes Mellitus (DM) is increasing worldwide at an unprecedented pace.
  • the International Diabetes Federation (IDF) estimates an upsurge from 382 million diabetics in 2013 to 592 million diabetics by 2030.
  • the World Health Organisation has declared it as a global epidemic.
  • the annual cost with diabetes management will increase from an approximate $376 billion in 2013 to $490 billion in 2030.
  • the management of DM involves strict glycaemic control with a target HbAlc of 7% to reduce complications.
  • Self-monitoring of blood glucose and self-knowledge of daily blood glucose increases compliance to medications and lifestyle measures and higher chances of achieving a target HbAlc.
  • Self-monitoring of blood glucose is also important in patients with type 1 diabetes who are at high risk of hypoglycaemia unawareness so that appropriate action can be taken on time.
  • the normal blood glucose concentrations are in the range of 4-8 mmol/L whereas pathophysiological blood glucose concentrations are in the range of 2-30 mmol/L in patients with DM.
  • SMBG self- monitoring blood glucose
  • CGMS Continuous glucose monitoring systems
  • CGMS was introduced as a minimal invasive solution, utilizing interstitial fluid (ISF) to estimate blood glucose (BG) values.
  • ISF interstitial fluid
  • BG blood glucose
  • Figure 14 shows a sensor-measuring glucose in the interstitial fluid. Micro-dialysis based approaches undergo an additional delay to extract ISF
  • CGM devices exhibit time delays when compared to capillary blood glucose. Short delays dependent on the membrane thickness are due to transit time effects due to diffusion through a glucose membrane. Micro-dialysis based approaches undergo an additional delay to extract ISF.
  • subcutaneous enzymatic sensor signal is typically in the nano-ampere range, where the current magnitude is proportional to ISF glucose. Additional filtering to smooth any electronic noise and artefacts is necessary, hence, creating a delay that is proportional to the amount of smoothing required.
  • three stages digital filtering comprising of moving average filter, nonlinear or linear rate limiting filter and data smoothing decimation filter is required. After which the multi-minute sensor signal is sent for calibration.
  • the total system delay reported by commercial invasive CGM products during steady-state operation is from 5 minutes to 12.6 minutes.
  • the current CGMS systems are extremely costly with the sensor cost dominating the long term.
  • Table 1 Shows various CGMS techniques along with their strengths and limitation.
  • Electromagnet k precision and against invasive basal and postic and heat employs before it can be used for glucose various NGM measurements; needs techniques; improvements in calibration
  • Laser SpectRx Uses 1. Requires daily calibration with a microporation Inc. invasive blood glucose meter.
  • ISF collecting device needs to be tics, Inc.)- glucose cone. fixed to skin and replaced every 3 skin 2. Good days.
  • Transdermal Prelude ® 1. Sensor warm 1. Requires skin permeation
  • a wearable device as described herein implements two different sensor technologies, which may have different ranges of optimal operation.
  • One of the technologies may be selected for ongoing monitoring so that blood glucose monitoring can be effected in the most accurate, efficient and convenient way possible for the wearer of the wearable device. Further, as the blood glucose values vary over time, this can be tracked more accurately and switching from one sensor technology to the other can be effected if the blood glucose values vary sufficiently.
  • Monitoring of the blood glucose values may be effected at a server, thereby minimising the processing burden on the wearable device itself, allowing
  • the wearer of the device may be able to use a program to interface between the wearable device and the server apparatus, with the programme being an executable program such as those used in personal computers and the like, or an app for use in a smart device, such as a smart phone, a tablet or a smart watch.
  • the system described herein is particularly suitable for fine tuning using data obtained over a period of time.
  • the wearable device and the server apparatus are configured to have their settings varied based on a machine learning algorithm which may be used to track the wearer's data and fine tune various system settings, such as switching thresholds and alarm conditions.
  • a machine learning algorithm which may be used to track the wearer's data and fine tune various system settings, such as switching thresholds and alarm conditions.
  • threshold and alarm conditions relating to monitoring for a
  • hypoglycaemic event For instance, while it is unlikely the setting at which an alarm condition is triggered would be changed, it may be that the level at which alert (e.g. a condition which needs to be alerted to the user, but not yet as serious as an alarm condition) are set can be varied by the user, preferably with input from a consulting physician, perhaps taking into consideration the user's medication regime and/or any changes thereto.
  • alert e.g. a condition which needs to be alerted to the user, but not yet as serious as an alarm condition
  • ear (lobe)/ear canal approximately can be attached to a smart watch for continuous measurement without degrading SNR.
  • Some alternate measurement sites included but not restricted are ear (lobe)/ear canal, arm, foot, etc.
  • One exemplary non-invasive continuous glucose monitoring system has its own proprietary algorithm and evaluated on the
  • the disclosed systems may not require multiple filtering stages as compared to known commercial continuous glucose monitoring systems. It may be possible to determine real time blood glucose hence minimising lag time caused by filtering when compared to interstitial fluid sensors.
  • the techniques disclosed can be implemented without detection using interstitial fluid analysis and, in these instances, there may be no physiological lead/lag when compared to measurement techniques requiring sampling of blood using finger pricking techniques.
  • Non-invasive blood glucose meter This could be, for example, integrated with an artificial pancreas to inject insulin into the body on an automatic basis.
  • Abnormalities in body parameters through continuous multisensory data analysis may be detected. For instance, by implementing one or more RF techniques as disclosed herein and, with some refinement of the algorithm(s) discussed, from analysis of data trends, from appropriate sensor placement (e.g. on the user's neck) it may be possible to detect hypo/hyper thyroidism.
  • Figure 1 is a block schematic diagram illustrating an exemplary system for monitoring blood glucose in a wearer of a wearable device
  • Figure 2 is a block schematic diagram illustrating an exemplary wearable device for monitoring blood glucose in a wearer of the wearable device
  • Figure 3 is a series of blood glucose measurement diagrams
  • Figure 4 is an architecture diagram illustrating system components
  • Figure 5 is a series of layout diagrams illustrating an exemplary wearable device for monitoring blood glucose in a wearer of the wearable device
  • Figure 6 is a diagram illustrating an exemplary method of wearing the wearable device of Figure 5;
  • Figure 7 is a graph illustrating a series of curves of relative permittivity versus frequency for six exemplary types of body tissue
  • Figure 8 is a graph illustrating a radar sweep for an exemplary radio-frequency blood glucose monitoring module
  • Figure 9 is a graph illustrating a series of blood glucose measurement values implementing the current non-invasive techniques compared with invasive techniques using a finger pricking technique
  • Figure 10 is a second graph illustrating the series of blood glucose measurement values of Figure 9 as time series values
  • Figure 11 is a Clarke Error Grid of the results from Figure 10;
  • Figure 12 is a series of Clarke Error Grids of historical blood glucose data obtained using a light spectroscopy technique
  • Figure 13 is a schematic diagram for the overall operation of a blood glucose monitoring system implementing a multi-sensor approach.
  • Figure 14 is a schematic layout diagram illustrating a known CGM sensor for measuring glucose in the interstitial fluid.
  • the system 100 comprises a server apparatus 102 for monitoring blood glucose.
  • Server apparatus 102 is configured to process data obtained by wearable device 104, worn by wearer 106, relating to blood glucose levels of the wearer.
  • server apparatus 102 communicates with the wearable device 104 through the wearer's computing device 108.
  • Server apparatus 102 comprises microprocessor 110, a memory 112 (e.g. a volatile memory such as a RAM) for the loading of executable instructions 114, the executable instructions defining the functionality the server apparatus 102 carries out under control of the processor 110.
  • Server apparatus 102 also comprises an input/output module 116 allowing server apparatus 102 to communicate with other devices.
  • User interface 118 is provided for user interaction and may comprise, for example, computing peripheral devices such as display monitors, computer keyboards and the like.
  • Server 102 comprises a data storage 120 for storing, for example, a database 122 of data relating to wearer 106 and, for example, historical blood glucose data and/or other sensor data.
  • Wearable device 104 comprises, principally, a radio-frequency blood glucose monitoring module 124 and a light spectroscopy blood glucose monitoring module 126. Wearable device 104 may also comprise a bio impedance sensor module 128 (depending on the system requirements) and an input/output module 130 allowing wearable device 104 to communicate with other devices. Wearable device 104 may have other components such as a microcontroller and a flash memory, but these are omitted from this figure for the sake of clarity.
  • the radio high-frequency blood glucose monitoring module 124 is configured for operation in the frequency range of 24 GHz to 24.25 GHz. It has been found that operation in this frequency range is particularly beneficial for a number of technical reasons. First, the depth of penetration in a user's skin area is greater when compared to the next ISM band of 61 to 61.5 GHz. Also, this is of course a short wavelength, and does not cause any damage to skin, or at the cellular level.
  • the RF signal related to variations in blood glucose is highly correlated as the RF signals can penetrate the cellular level where the cellular membrane permittivity changes can be measured with respect to changes in the blood glucose concentration. At the 24 GHz ISM band, an observable drop in the permittivity for different layers can be observed; see, for example, Figure 7. In this race, changes in blood glucose only effect the permittivity of blood, and this can be measured through the techniques described herein.
  • exemplary wearable devices may have a flex cable installed.
  • the flex cable is required to transmit and receive this high-frequency 24 GHz signal, so the dielectric layer between the conductive flex layers has to be extremely low to reduce losses at board level. From a cost and manufacturing perspective, it is extremely costly and difficult to achieve high yield high-frequency flex boards. Further, the ISM band of 61 GHz exhibits high losses in human tissue, and may be absorbed by the atmosphere, by water and the like.
  • the integrated chips are manufactured utilising special low transistor node technologies, implementing for example, a silicon germanium process with high ft (unity gain current frequency) in order to implement mm wave (61 GHz ISM band) circuits. Operation in this frequency range allows realisation benefit from a manufacturing perspective.
  • Figure 5 (described in more detail below) referring to the flex cable
  • Computing device 108 comprises a microprocessor 132, a memory 134 (e.g. a volatile memory such as a RAM) for the loading of executable instructions 136, the executable instructions defining the functionality the computing device 108 carries out under control of the processor 132.
  • Computing device 102 also comprises an input/output module 138 allowing the computing device 108 to communicate with other devices.
  • User interface 140 is provided for user interaction and may comprise, for example, computing peripheral devices such as display monitors, computer keyboards and the like. If the computing device 108 is, say, a smart phone, tablet device or smart watch, the user interface 140 is likely in the form of a touch panel display as is prevalent in many smart phone and other handheld devices.
  • Server apparatus 102 is configured for communications through communications network 142 (e.g. the Internet) and communications channel 144, which may be a wired or a wireless link, or a combination of both.
  • Computing device 106 is configured for communications through communications network 142 and communications channel 146, which may be a wired or wireless link, or a
  • Wearable device 104 is configured for communications with computing device 108 through communications channel 148, which may be a wired or a wireless link, or a combination of both.
  • communications channel 148 is a Bluetooth (TM) channel, with both wearable device 104 and wearer computing device 108 having associated hardware and software therefor.
  • Direct cable connections using, for example, a USB protocol are also contemplated.
  • a cable connection may offer the advantage that any battery in the wearable device (omitted from Figure 1 for the sake of clarity) may also be charged through the cable connection.
  • wearable device 104 is configured to communicate through another communications channel (not shown) through communications network 142 with server apparatus 102. That is, these communications are not routed through computing device 108.
  • a headless router server akin to an Internet router with an additional software stack, can be used to transmit data or receive data from a Bluetooth communication chip using the IPv4 or IPv6 software stack running on the Bluetooth chip.
  • Server apparatus 102 may be a single server as illustrated schematically in Figure 1, or have the functionality described above distributed across separate servers, and each of the separate servers may have its own hardware components corresponding to those illustrated in Figure 1.
  • References herein to "a microprocessor", "a memory” and the like are not necessarily to be considered limiting as applying to one and only one microprocessor operating in one and only one server apparatus, unless this is specifically stated.
  • Figure 2 provides a more detailed block diagram of the wearable device 104.
  • Figure 2 illustrates again the radio-frequency blood glucose monitoring module 124, the light spectroscopy blood glucose monitoring module 126, the bio impedance sensor module 128 and the input/output module 130. The interface between the input/output module 130 and communications channel 148 is also illustrated.
  • wearable device 104 also comprises a power
  • Signal conditioning block 203 provides gain and filtering functionality for data received from one or more of modules 124, 126, 128 prior to conversion by analogue to digital converter 204.
  • Radio-frequency module 124 communicates with one or more antennas (not shown in Figure 2, but refer to Figure 4) on line 206.
  • Light spectroscopy module 126 communicates with and/or powers a light source (not shown in Figure 2, but refer to Figure 4) on line(s) 208.
  • Light spectroscopy module 126 communicates with and/or powers a photosensor (not shown in Figure 2, but refer to Figure 4) on line(s) 210.
  • Suitable photosensors include one or more from Silicon, Silicone Germanium, Indium Gallium Arsenite, Gallium Phosphite, Germanium, and quantum dots.
  • Bio impedance sensor module 128 communicates with and/or powers a first set of bio impedance sensors/sensor electrodes (not shown in Figure 2, but refer to Figure 4) on line(s)
  • Bio impedance sensor module 128 communicates with and/or powers a second set of bio impedance sensors/sensor electrodes (not shown in Figure 2, but refer to Figure 4) on line(s) 214.
  • Concerning radio-frequency blood glucose monitoring module 124 this implements a dielectric spectroscopy sensing technique which measures the permittivity of the wearer's body - or a part thereof - with respect to change in blood glucose concentration at a given frequency. This technique can be
  • a localised site of measurement i.e. wrist or finger or skin flap between index finger and thumb, etc.
  • Other suitable measurement sites include, for example, the earlobe.
  • FIG. 3 is a series of blood glucose measurement diagrams. Turning first to Figure 3(a), this illustrates a first range 300 of operation across a first range of blood glucose values for the radio-frequency blood glucose monitoring module 124.
  • first range 300 corresponds with a range of optimal operation of the radio-frequency blood glucose monitoring module 124 from a lower blood glucose value 302 to an upper blood glucose value 304.
  • lower blood glucose value 302 is 0 mg/dL.
  • upper blood glucose value 304 is 360 mg/dL.
  • Range 300 represents a range of operation of the radio-frequency blood glucose sensor module in which the module's response is at least generally linear, therefore providing acceptable measurement results.
  • FIG 3 (b) there is illustrated a second range 306 of operation across a second range of blood glucose values for the light spectroscopy blood glucose monitoring module 126.
  • second range 306 corresponds with a range of optimal operation of the light spectroscopy blood glucose monitoring module 126 from a lower blood glucose value 308 to an upper blood glucose value 310.
  • lower blood glucose value 308 is 36 mg/dL.
  • lower blood glucose value 308 is 72 mg/dL.
  • upper blood glucose value 304 is 500 mg/dL.
  • Range 306 represents a range of operation of the light spectroscopy blood glucose sensor module in which the module's response is at least generally linear, therefore providing acceptable measurement results.
  • the first and second ranges 300, 306 have a range of overlap 312 - from lower value 308 of second range 306 up to upper value 304 of the first range 300 - in which both sensor modules 124, 126 exhibit acceptably linear performance.
  • An initial reference blood glucose value for the wearer of device 104 is taken from an invasive finger prick blood glucose test, and communicated to server apparatus 102. In one implementation, the initial reference blood glucose value is entered by the wearer at computing device 108 and communicated therefrom to server apparatus 102.
  • the initial reference blood glucose value may be transmitted automatically and/or directly to the server from, for example, a non- Bluetooth blood glucose meter. In such a way, it is not necessary for the user to enter the results into computing device 108.
  • the initial finger prick value may be communicated directly from the wearable device (assuming it has a suitable transmitter) or it may be transmitted automatically to a computing device such as computing device 108.
  • a customised device is provided to acquire the finger prick value and to communicate this to a computing device, such as computing device 108.
  • the customised device may be a Bluetooth enabled custom printed circuit board which can be connected to any non-Bluetooth blood glucose meter, and the finger prick data to be used for the initial and daily calibration transmitted to computing device 108 using the Bluetooth protocol. This obviates the requirement for the user to enter the finger prick value, and may enable the noninvasive wearable sensor and the blood glucose meter seamlessly synchronising their system timings to define the precise moment of calibration data.
  • the customised device may run one or more protocols depending on the model of the blood glucose meter in order to extract the finger prick value from the meter.
  • Server apparatus 102 initially sets a threshold blood glucose value 314 as illustrated in Figure 3(c).
  • the threshold blood glucose value is set at 300 img/dL, although other values are also contemplated where appropriate.
  • the initial threshold blood glucose value lies in the range of overlap 312. In the range of overlap 312, there may be a sub-range 316 of blood glucose values lower than the threshold blood glucose value 314 and a sub-range 318 of blood glucose values higher than the threshold blood glucose value 314.
  • Server apparatus 102 is configured to compare the initial reference blood glucose value with the threshold blood glucose value 314 and, therefrom, determine which of the radio-frequency blood glucose monitoring module 124 and the light spectroscopy blood glucose monitoring module 126 is best suited to performing ongoing (e.g. continuous) blood glucose monitoring in the environs of the reference glucose value. For example, it may be that the initial reference blood glucose value is a value lower than lower value 308 of the second range of operation 306 of the light spectroscopy blood glucose monitoring module 126, thereby indicating that radio- frequency blood glucose monitoring module 124 will exhibit more accurate performance than light spectroscopy blood glucose monitoring module 126 for blood glucose values of that order. Thereafter, ongoing non-invasive blood glucose monitoring may be conducted by server apparatus 102 using the measurement data obtained by radio-frequency blood glucose monitoring module 124.
  • the initial reference blood glucose value is a value higher than upper value 304 of the first range of operation 300 of the radio-frequency blood glucose monitoring module 124
  • ongoing non-invasive blood glucose monitoring may be conducted by server apparatus 102 using the measurement data obtained by light spectroscopy blood glucose monitoring module 126.
  • either of the RF or light spectroscopy techniques can be selected for the initial ongoing monitoring, as long as the selected technique is acceptably linear in that range of operation.
  • the initial reading yields a blood glucose value of 200 img/dL and the light spectroscopy sensor data is selected initially for ongoing monitoring.
  • the pathophysiological rate limited for glucose change per minute is known. If blood glucose concentration increases or decreases, the predicted output from the sensor changes accordingly. Thereafter, if the sensed blood glucose value approaches or crosses the threshold, the RF sensor data is then selected for ongoing monitoring.
  • server apparatus 102 may perform the selection simply on the basis of the initial reference blood glucose value being in the first sub-range 316 - thus indicating that the radio-frequency blood glucose monitoring module 124 may be better suited to the blood glucose monitoring to be conducted, at least initially - or in the second sub-range 318, indicating that the light spectroscopy blood glucose monitoring module 126 may be better suited to the blood glucose monitoring to be conducted, at least initially.
  • Figure 1 illustrates a server apparatus 102 for monitoring blood glucose in a wearer 106 of a wearable device 104, the server apparatus 106 comprising a processor 110 and a memory 112, the server apparatus 102 being configured, under control of the processor 110, to execute instructions
  • Server apparatus 102 stored in the memory 112: to perform a first mode of operation of blood glucose monitoring for the wearer 106 of the wearable device 104 using data obtained by a radio-frequency blood glucose monitoring module 124 in the wearable device 104.
  • Server apparatus 102 is also configured to perform a second mode of operation of blood glucose monitoring for the wearer 106 of the wearable device 104 using data obtained by a light spectroscopy blood glucose monitoring module 126 in the wearable device 104.
  • Server apparatus 102 may then perform a threshold comparison between a reference blood glucose value for the wearer 106 of the wearable device 104 and a threshold blood glucose value 314.
  • Server apparatus 102 selects a first one of the first mode of operation and the second mode of operation in dependence of the threshold comparison. A corresponding method is also described.
  • server apparatus 102 selects one of the modules 124, 126 as the initial module from which blood glucose measurement data will be taken for ongoing monitoring of blood glucose of the wearer 106.
  • server apparatus 102 may also be provided in the wearer's computing device 108.
  • the wearer's blood glucose values may change to an extent that blood glucose measurement may more accurately be determined using the other of the modules 124, 126.
  • the initial selection by server apparatus 102 has been for the ongoing blood glucose monitoring to be determined based on the measurement data obtained by the radio-frequency blood glucose monitoring module 124.
  • a measured value of blood glucose 320 - which may be a blood glucose value 320 determined by server apparatus 102 on the basis of the raw measurement data from the radio-frequency blood glucose monitoring module 124 - is illustrated in sub region 316 of the range 312 of overlap.
  • the raw measurement data obtained from the radio-frequency blood glucose monitoring module 124 indicates that the measured (determined) value 320 increases above the initial threshold value 314, as indicated by arrow 324.
  • server apparatus 102 is configured to determine that, given the increase in the measured/determined value 320, more accurate monitoring may be conducted by the light spectroscopy blood glucose monitoring module 126.
  • the initial selection by server apparatus 102 has been for the ongoing blood glucose monitoring to be determined based on the measurement data obtained by the light spectroscopy blood glucose monitoring module 126.
  • a measured value of blood glucose 322 - which may be a blood glucose value 322 determined by server apparatus 102 on the basis of the raw measurement data from the light spectroscopy blood glucose monitoring module 126 - is illustrated in sub region 318 of the range 312 of overlap.
  • server apparatus 102 is configured to determine that, given the decrease in the measured/determined value 322, more accurate monitoring may be conducted by the radio-frequency blood glucose monitoring module 124.
  • the range 312 of overlap may be across a range of 100 mg/dL, where both methods are acceptably linear.
  • Figure 3 illustrates the radio-frequency blood glucose monitoring module 124 has a first range of operation 300 across a first range of blood glucose values 302, 304 and the light spectroscopy blood glucose monitoring module 126 has a second range of operation 306 across a second range of blood glucose values 308, 310, the first range 300 and the second range 306 having a range of overlap 312.
  • the server apparatus 102 is configured for the threshold blood glucose value 314 to be in the range of overlap 312; and the server apparatus 102 is configured to determine when a measured value 320, 322 of blood glucose for the wearer 106 crosses the threshold 314 during blood glucose monitoring and, in dependence of the determination, to select a second one of the first mode of operation and the second mode of operation.
  • crosses the threshold means when the determined blood glucose value 320, 324 goes from below the threshold to above it, or from above the threshold to below it.
  • Figures 1 and 3 illustrate a server apparatus 102 for monitoring blood glucose in a wearer 106 of a wearable device 104, the server apparatus 102 comprising a processor 110 and a memory 112, the server apparatus 102 being configured, under control of the processor 110, to execute instructions 114 stored in the memory 112: to perform a first mode of operation of blood glucose monitoring for the wearer 106 of the wearable device 104 using data obtained by a radio-frequency blood glucose monitoring module 124 in the wearable device 104, the radio-frequency blood glucose monitoring module 124 having a first range of operation 300 across a first range of blood glucose values 302, 304; to perform a second mode of operation of blood glucose monitoring for the wearer 106 of the wearable device 104 using data obtained by a light spectroscopy blood glucose monitoring module 126 in the wearable device 104, the light spectroscopy blood glucose monitoring module 126 having a second range 306 of operation across a second range of blood glucose values 308, 310, the first range
  • the Applicant has found that incorporation of a bio impedance reading into the determination of the measured/determined blood glucose value 320, 322 crosses the threshold 314.
  • the bio impedance reading may be taken from any bio impedance sensor or from the bio impedance sensor module 128 in the wearable device 104, when one is provided.
  • server apparatus 102 receives measurements from the bio impedance sensor module 128 which includes a component relating to the skin resistance, capacitance and/or phase of the wearer, for example for a localised area of skin around the bio impedance sensor. Any changes in the skin
  • resistance/capacitance/phase are indicative of a change in blood glucose for the wearer 106.
  • a change in blood glucose for the wearer 106 For example for one individual, under similar environment settings will have a particular resistance X ohms for a certain blood glucose value Y mg/dL.
  • X+deltaX When the Blood glucose value increases from Y to Y+deltaY, there is a corresponding change in the (local) skin resistance from X to, for instance, X+deltaX.
  • the preferred mode of operation - which one of the radio-frequency or the light spectroscopy sensor modules 124, 126 to use data from - can be selected. For instance, a weight of either 0 or 1 is assigned to either the RF or the optical method.
  • server apparatus 102 may be configured so that this threshold value is variable, to be set either by monitoring personnel or variable responsive to observations made data received during ongoing monitoring, for example, changes in the user's body make up, such as a change in (e.g. "local" body mass index, as may be measured with a BMI sensor in the apparatus 102). That is, server apparatus 102 is configured to vary the threshold blood glucose value.
  • this threshold value is variable, to be set either by monitoring personnel or variable responsive to observations made data received during ongoing monitoring, for example, changes in the user's body make up, such as a change in (e.g. "local" body mass index, as may be measured with a BMI sensor in the apparatus 102). That is, server apparatus 102 is configured to vary the threshold blood glucose value.
  • server apparatus 102 may assign weight 0 to the optical sensor module 126 and weight 1 to the RF sensor module 124 until the determined blood glucose value reaches the threshold value, in this instance 300 mg/dL.
  • the threshold value in this instance 300 mg/dL.
  • server apparatus 102 is configured to perform blood glucose monitoring by applying a weighting factor to at least one of determined first non-invasive measured blood glucose values and second non-invasive measured blood glucose values.
  • Figures 1 and 3 illustrate a server apparatus 102 configured to determine a bio impedance value for the wearer 106, the bio impedance value being obtained by data received from a bio impedance sensor 128; and to determine when a measured (determined) value 320, 322 of blood glucose for the wearer 106 crosses the threshold using the bio impedance value.
  • Ongoing monitoring of the determined value 320, 322 allows server apparatus 102 to track any alarm conditions of which the wearer may need to be aware. For example, if blood sugar becomes too low or too high (indicating a hypoglycaemic or a hyperglycaemic event), and alarm can be generated. It is useful to notify the wearer of the device of such an impending event so that the user may take preventive action, such as consuming medication and/or food in order to reduce the risk of the event occurring.
  • the alarm can be generated in any one of a number of ways. For instance, server apparatus 102 can transmit information to the user's computing device for the alarm to be generated thereat. Additionally or
  • the wearable device 104 may be configured to emit an alarm such as an audible signal, or to generate a vibration action or similar.
  • the weighting factors may be applied by server apparatus 102 implementing the instructions 114 (software code) loaded into the memory 112 of the apparatus 102. Additionally or alternatively, some form of hard-circuit switching may be effected to switch from one set of measurements to the other.
  • FIG 4 provides an alternative illustration of the system architecture.
  • machine learning and weight assignment functions are optional. Some more detail referring to machine learning is given with respect to Figure 13 but, in summary, this can be used to determine optimal monitoring parameters for individual users based on the individual users' characteristics, and to set, for example, alarms for, say, hypoglycaemic and hyperglycaemic events accordingly. These results may be fine-tuned from additional data for the user, such as the user's heart rate, body temperature, pulse oximetry, sleep cycle, exercise activities and food intake, to name but a few.
  • Figure 5 provides a series of layout views of an exemplary wearable device 104.
  • Figure 5(a) is an elevation view of the side of the wearable device intended to be worn against the user's skin
  • Figure 5(b) is a side view
  • Figure 5(c) is an elevation view of the side of the wearable device intended to be worn away from the wearer's skin.
  • the exemplary device of Figure 5 is comprised of a generally flat substrate 500 having a flexible section 502 about which fold lines may be made, the reasons for which will become apparent when reading Figure 6.
  • Contact regions 506 are provided on either side of the flexible region 502, each of the contact regions having radio-frequency (patch) antennas 508 affixed thereto or mounted thereon, the antennas 508 forming part of the radio-frequency sensor module 124. Additionally or alternatively, other types of antennas may be used, for example slot antennas.
  • the radio-frequency IC chip may be provided with an antenna on its substrate to radiate the radio-frequency signals.
  • Light spectroscopy module 126 in this example, comprises a light source such as LED 510, photodiode 512 signal conditioning module 514.
  • Wearable device 104 comprises first and second sets of bio impedance sensor electrodes, 516, 518, for positive and negative electrodes respectively.
  • An accelerometer 520 and/or a temperature sensor 521 may also be provided.
  • the PCB layer portions 522 are best viewed in Figure 5 (b), along with the RF IC 524 and the laminate fixture layers 526.
  • a battery 528 is provided.
  • a flexible cable 530 is used to join the section having the OLED display 532 to the sensor section.
  • Figures 1, 2 and 4 illustrate a wearable device 104 for blood glucose monitoring, the wearable device comprising: a radio-frequency blood glucose monitoring module 124 for obtaining a first non-invasive measured blood glucose measurement for a wearer 106 of the wearable device 104.
  • a light spectroscopy blood glucose monitoring module 126 is provided for obtaining a second non-invasive measured blood glucose measurement for the wearer of the wearable device.
  • a transmitter module 130 is provided for transmitting the first non-invasive measured blood glucose measurement and the second non-invasive blood glucose measurement to a second device, such as the user's computing device 108 and/or the server apparatus 102. A corresponding method is also described.
  • the wearable device 104 may comprise a bio impedance monitoring module 128. This may be provided for obtaining a bio impedance measurement for the wearer 106 of the wearable device 104, and wherein the transmitter module 130 is configured to transmit the bio impedance measurement to the second device 102, 108.
  • Figure 1 illustrates a computing device 108 comprising a processor 132 and a memory 134, the computing device 108 being configured, under control of the processor 132, to execute instructions 136 stored in the memory 134 to communicate information between the server apparatus 102 and the wearable device 104. A corresponding method is also described.
  • Figure 6 illustrates one way of wearing the wearable device 104 illustrated in Figure 5.
  • the device is worn on a part of the user's body, in this example the user's hand.
  • the device folds around the area in the user's hand between the thumb and the forefinger.
  • the fold is around the fold lines 504 in the flexible section 502.
  • other types of wearable devices are
  • These may be worn on other parts of the body, such as the arm (or wrist) or on the ear, such as clipped to an ear lobe.
  • the bio impedance sensor may be configured to measure a "localised" bio impedance value for the localised area 602 around the area of the wearable device.
  • the extent and size of the localised area 602 depends on a number of factors including the wearer of the device, and the characteristics of the electronic components in the wearable device.
  • the localised area may be an area such as the area 602 illustrated in Figure 6 or another area, such as the wearer's arm below the elbow, or the whole arm.
  • sensed signals obtained by radio-frequency blood glucose monitoring module 124 may be communicated to the server apparatus 102 via communications network 142.
  • Server apparatus 102 is configured to process the received data to detect a change in blood glucose level for the wearer.
  • server apparatus 102 may be configured to implement one or more algorithms using scattering parameter (S-parameter such as the S12 parameter) techniques in one or more of the time domain and also in the frequency domain.
  • S-parameter such as the S12 parameter
  • the raw data from the module 124 (and from module 126, for that matter) may be communicated using any suitable communications protocol, such as the TCP/IP protocols, LTE protocols, or, say, the short messaging service (SMS).
  • the permittivity measurement is obtained using a CW/FMCW (radar) chip in the wearable device 104, for example in the radio-frequency blood glucose monitoring module 124.
  • the variation in permittivity can be measured through the detection of phase difference between the input and output wave, and may provide a simple and low cost solution for this purpose.
  • Use of continuous wave modulation may be considered particularly beneficial when precise voltages have to be generated to control a voltage-controlled oscillator in a high-frequency integrated circuit chip used in the product.
  • the high-voltage may be generated by a stable ultralow noise digital to analog converter.
  • the digital to analog converter for the wearable device has to be ultralow power, and when the digital to analog converter requires an output buffer to provide for impedance to the voltage-controlled oscillator, other modulation protocols such as FMCW may require the digital to analog converter to operate at high-frequency (determined by the bandwidth of the FMCW chip and the duration of the sweep interval).
  • FMCW modulation scheme will cause higher power consumption and result in frequent charging/discharging of the battery, something which may be considered undesirable, particularly for a wearable device which may be intended for use over a prolonged period.
  • radio-frequency blood glucose monitoring module 124 senses a combined permittivity value for all different layers of skin as a single permittivity reference value. This is then correlated/calibrated to a known blood glucose value taken from a Blood glucose finger prick invasive test. Since the permittivity of the blood changes as the blood glucose concentration varies, this absolute permittivity for the combined skin changes in a similar fashion, which is detectable by dielectric spectroscopy, for example in the frequency domain. The determined blood glucose value may also be converted into the time domain as well.
  • a vector network analyser that measures S-parameters of materials may be employed to measure permittivity of a material, and/or other material properties.
  • Permittivity ( r ) can be extracted using, for example, the steps described in [12].
  • the Cole-Cole model for quantizing glucose dependent changes in electrical property can also be used.
  • ⁇ is the angular frequency
  • e' c ( ) is the frequency dependent dielectric constant
  • e" c ( ) is frequency dependent dielectric loss
  • n is the order of the Cole- Cole model
  • e ⁇ is high frequency permittivity
  • Ae n is the magnitude of the dispersion
  • a n is the parameter that allows for the broadening of the dispersion
  • ⁇ is the static ionic conductivity.
  • Figure 7 is a graph illustrating a series of curves of relative permittivity versus frequency for six exemplary types of body tissue [9].
  • this shows how the permittivity of the layers 700 of dry skin, wet skin, muscle, blood, brain/white matter and fat vary with variations in the frequency of the applied radio- frequency wave.
  • This region 702 corresponds with the range of operation 300 of the RF sensor module 124, as illustrated in Figure 3(a). So, while monitoring the data received from the RF sensor module 124, received as a series of signals from the wearable device 104, server apparatus 102 is able to detect a change in blood glucose from changes in the permittivity value.
  • server apparatus 102 is configured to associate the data received from the radio-frequency blood glucose monitoring module as a series of combined values for plural tissue layers in the wearer's body, and to determine a change in blood glucose for the wearer from a determination of first and second combined values in the series of combined values being different from one another. Also, server apparatus 102 may be configured to associate the data received from the radio- frequency blood glucose monitoring module 124 as a series of combined permittivity values.
  • radar is used to detect moving objects, and parameters such as the distance and speed.
  • System 100 can be used to implement a novel way of using FMCW radar to measure one or more of absorption, delay, and phase of wave propagation in the blood which can be used to extract the amount of blood glucose. Other modulation schemes, including CW are contemplated.
  • ⁇ and ⁇ are approximately independent of glucose level and R is fixed for an individual. So the variation in ⁇ will be represented in the measured attenuation. Measuring the amplitude of the wave can be done through FMCW, CW or another modulation scheme instead of an expensive vector network analyzer.
  • variation in permittivity can be also measured through the phase difference between the input and output wave, by employing FMCW or other radar for this purpose.
  • ⁇ is the time delay taken by the transmitted waveform to the target at distance R.
  • R can also be determined for a particular person by using a device similar to a digital vernier calliper.
  • the glucose monitoring sensor may have to be worn on a continuous basis, the first time a user uses the device, he (or she) may have to apply the sensor patch to the measurement site and the RF/mm-wave IC will generate signals such as FMCW. Since R is fixed for one user and ⁇ can be found out from the FFT (Fast Fourier Transform) signal processing in the baseband, the value of c £ which is medium- dependent may be taken as the first reference point for calibration of subsequent sensor signals. This value of c £ may be stored in the microcontroller or software on the phone (and/or at server level) along with the Blood Glucose finger prick value to serve as the calibrated reference point for further non-invasive sensor readings.
  • FFT Fast Fourier Transform
  • Phase information may be extracted from this time delay ⁇ . There is a phase shift observed during experimentation when blood glucose rises.
  • Figure 8 illustrates a radar sweep for a RF module implementing FMCW, the second exemplary method, fo is the starting frequency; fi is the end frequency of the linear increasing sweep; B is the bandwidth which is difference between fi and fo; T is the sweep period.
  • ⁇ is the time delay taken by the transmitted waveform to the target at distance R and to return.
  • c £ is the velocity of light in the medium.
  • the medium is biological skin or the interested measurement site.
  • the beat frequency (fe) is given by equation 5
  • a simplified effective permittivity (£ e ff) can be calculated as-
  • the velocity of light is dependent on the permittivity of the medium.
  • the current approach may use combined permittivity values (£ e ff) for all different layers of skin as one single permittivity reference value which is correlated to the Blood glucose finger prick value. Since, the permittivity of the blood changes as the blood glucose concentration increases, this absolute permittivity for the combined skin increases in a similar fashion, hence the time delay ⁇ also increases and the c £ decreases, increasing the beat frequency fe.
  • a fast Fourier transform can be performed on the beat frequency to reveal the amplitude and/or frequency shift information.
  • Sensed signals obtained by light spectroscopy blood glucose monitoring module 126 may also be communicated to the server apparatus 102 via communications network 142.
  • Server apparatus 102 is configured to process the received data to detect a change in blood glucose level for the wearer. For instance, server apparatus 102 may be configured to implement one or more algorithms to that end.
  • Near infrared light is an attractive method as it can deeply penetrate into the tissue to determine the amount of blood glucose [6].
  • the amount of light scattered decreases with an increase in the amount of blood glucose content.
  • a photodiode and light source can be used to estimate the amount of blood glucose.
  • previous experiments conducted by one of the inventors in the current application [7] suggest that the variation of tissue thickness, for example, ear lobe thickness (which can be used as a measurement site) and skin tone can contribute to the degradation of the correlation coefficient of near infrared light, and mid infrared light with respect to the amount of blood glucose. The degradation of the correlation coefficient makes this method less suitable if it is used as the only method to determine blood glucose for multiple individuals without calibration.
  • Figure 9 is a graph illustrating a series of blood glucose measurement values implementing the current non-invasive techniques compared with invasive techniques.
  • the continuous predicted blood glucose is given with respect to reference blood glucose of a healthy human volunteer using the radio-frequency method.
  • This experiment was conducted for an 87-minute duration during which sugar drink and chocolate cookies were consumed 18 minutes apart. Distinct sensor peaks can be observed in the 45 th and 62 nd minutes of the experiment (indicated by the solid line).
  • Blood Pricks using a One Touch Ultra (TM) device were taken every 5- 7 minutes to verify the surge in blood glucose near the sensor peaks (indicated by the chain line). Rate limiting filtering was applied to the raw sensor data, indicated by the dashed line. The sensor yields non-Invasive data every 60 seconds. It has been found that data, when plotted on the Clarke error grid, can satisfy the IS015197 standard.
  • Figure 11 is a Clarke Error Grid of the results from Figure 10.
  • Figure 12 shows the results from comparing the non-invasive near infrared (NIR) light spectroscopy with respect to blood glucose results for an individual as well as multiple individuals.
  • Figure 12 (a) shows the potential of a NI-CGMS system using the NIR approach described herein, where the data is taken along with an invasive blood glucose test two times for 4 days in an uncontrolled and non-calibrated
  • Figure 12(a) shows non-invasive result of blood glucose value vs. NIR light source for an Individual with type 1 diabetes
  • Figure 12(b) shows the result of blood glucose value vs. NIR light source for multiple Individuals with or without diabetes.
  • server apparatus 102 is configured to compare the measured blood glucose value with historical blood glucose data and, from the comparison, to determine a change in blood glucose for the wearer.
  • Historical blood data may comprise data obtained from the wearer, whether from module 124 or from module 126, or of data obtained from a group of sample subjects (each of whom may or may not have diabetes).
  • the apparatus 102 is configured to compare the measured blood glucose value with a slope-intercept equation from the historical data of the non-invasive sensor(s).
  • measured blood glucose value may refer to the raw data obtained by the sensor(s) in the modules 124, 126, or this raw data, after it has been processed by server apparatus 102.
  • a machine learning algorithm may be used to monitor or track the data obtained by the sensors 124, 126 in the wearable device 104.
  • the tracked data may be used to refine/fine-tune system data, such as the thresholds at which the switching between RF sensor data and optical sensor data, and/or the thresholds at which alarms may be generated.
  • a complete non-invasive continuous glucose monitoring system solution may not only lie in the above-described hardware, but also in a machine learning algorithm which may be implemented in, for example, an android/iOS application, in one or more servers (for example one or more cloud servers), in an embedded real-time operating system in a fixed or mobile device, or at least a component of the algorithm being implemented therein.
  • Unsupervised learning and reinforcement learning approaches can be one set of methods that can be applied to dynamically update the weights assigned to the two non-invasive methods to determine blood glucose.
  • bio impedance may be measured locally (ear lobe, arm, nostril, leg etc.) to see the changes in terms of capacitance, resistance, phase to suggest automatic changes in calibration requirement.
  • server apparatus 102 may be configured so that the algorithm will define a new calibration reference point i.e. a new capacitance value and new light spectroscopy reference sensor value which will serve as reference calibration point for subsequent non-invasive sensor readings.
  • the server apparatus is configured to calibrate (or re-calibrate) historical data relating to the wearer based on a change in the bioimpedance value.
  • FIG. 13 shows an exemplary correlation coefficient and weight assignment scheme to enhance the total correlation of multi-sensor method, in order to predict blood glucose content which is clinically acceptable.
  • Bio-impedance along with pulse oximetry and/or heart rate can be used to precisely determine and predict impending hypoglycaemic events during sleeping.
  • the user's heart rate is expected to rise, as the user mounts an autonomic causing tachycardia.
  • some patients may not exhibit a rise in heart rate with hypoglycaemia if they have a problem in the autonomic nervous system.
  • Machine learning uses inputs/features/trends from wearer's heart rate, exercise patterns, sleep cycles (including duration), temperature (core/skin) as optional parameters which, when used, help to enhance the accuracy of the switching threshold for bio impedance. These optional parameters are unique for every individual and hence the weight assignment for the neural network layers vary, and linear regression /non-linear regression techniques can be used depending on the input data (or training data) to the machine learning system.
  • Implementation of neural networks/machine learning techniques on the gathered user data may be effected. Upon gathering sufficient data, the machine is trained using this data and the subsequent sensor data does not require calibration from the user (in terms of the SMBG finger pricks).
  • the weights assigned to neural network layers may not be similar for all individuals. Data trends from heart rate, exercise, sleep patterns, local bio impedance, and pulse oximetry can be used:
  • Machine learning may work on the following principle.
  • Features from the RF wave signals may be analysed in the time and frequency domain.
  • Features in the time domain mean, median, variance, standard deviation, time delay
  • Features in the frequency domain include signal power, magnitude, total spectrum power, noise power spectrum, normalized power (normalized power of the spectrum may be computed in intervals for example every 10 minutes, with the frequency of the CGM in this example being 10 minutes), and frequency shift.
  • the capacitance of the different skin/tissue layers - fat, wet skin, dry skin, blood, bone for example - may be taken as one unified capacitance which serves as the reference for the combined permittivity.
  • Changes in the permittivity of the red blood cell count due to changes in blood glucose can be measured using, for example, one of the RF wave techniques described above.
  • the CGM utilising RF wave for prediction of blood glucose is feasible for implementing in a non-controlled environment.
  • the correlation coefficients aj to ej of various methods proposed may be included inside a machine learning algorithm for it to adapt to a dynamic measurement environment. This reduces the amount of calibration required by the CGMS from an average twice per day to once per day after an estimated first month of using the proposed NI-CGMS technique(s). After sufficient user data have been obtained, using both invasive and non-invasive techniques, a zero calibration scheme may be realised. Deep learning algorithms along with the proposed multi-sensor approach can be implemented to achieve this zero calibration scheme.
  • the user upon the first usage of the system, the user is instructed to calibrate upon system start indicated as point 1 in the calibration block. This is done to calculate the minimum and maximum thresholds for individual sensors.
  • the user wears the sensor patch and the second point of calibration is taken (preferably before consuming food).
  • Point 3 of the calibration is taken 20-30 minutes after consuming food. This is done to get the direction of phase shift (or the parameters we are measuring example delay, frequency domain analysis) and record changes in the sensor parameters. Note calibration points 1 to 3 may need to be done only once during the sensor lifetime.
  • Calibration points 4and 5 are to be done daily approximately after every 12 hours. It is predicted that upon continuously using the NI-CGMS device, the calibration can be reduced to once per day. Eventually after sufficient data points of both invasive and non-invasive methods are available in our system, zero calibration can be achieved with the help of deep learning and multi-sensor data.
  • Server 102 may implement a bio-impedance measurement component to compute user parameters such as respiration rate, fat percentage and water content and sleep cycle/stage. Pulse oximetry may be used to calculate oxygenated
  • Deoxygenated blood counts and pulse rate/heart rate.
  • Temperature reading comprising of ambient and skin surface may be taken.
  • Sensed bio-impedance, pulse oximetry, and temperature data can serve as correction factors for the two methods - light spectroscopy and dielectric spectroscopy to compute blood glucose content.
  • RF/mmwave/terahertz in combination with machine learning and deep learning algorithms may be used to assign respective weights for the data obtained using the light spectroscopy and dielectric spectroscopy methods.
  • the approximate regions of high and low blood glucose can be precisely determined with the help of multi-sensors for example, bio-impedance, pulse oximetry, heart rate and temperature sensors.
  • the sensors shown in the Figure 13 are shown as having a multiplicity of detection parameters.
  • implementations of devices and/or systems, as described herein, may include fewer sensor components or detection parameters and remain within the scope of the disclosure. Alternately, other implementations of devices and/or systems may include additional components, sensors, or various combinations of the described components, sensors, and remain within the scope of the disclosure.
  • the main algorithm combining machine learning, deep learning, multi-sensor data is used to predict blood glucose results and provide hypo/hyperglycaemic alerts.
  • the proposed system with the usage of multiple parallel sensors (dielectric spectroscopy, light spectroscopy and local bio impedance sensors) and additional parameters (local BMI, skin thickness, heart rate, pulse oximetry, temperature(core, skin), movement tracker, food intake, for example) maximizes the signal to noise ratio and sensitivity required for clinical acceptance.
  • a highly integrated multiple sensor patch can be placed onto a skin fold with no irritation.
  • a wearable device akin to a pedometer can be used.
  • An optional heart rate sensor to increase sensitivity in detecting hypoglycaemia without a lag time may be integrated into the multi-sensor approach.
  • the collected non-invasive CGMS data is evaluated for alerting impending hypoglycaemic and hyperglycaemic events based on multiple parameters. Using the described techniques, clinical precision may be attained.
  • the devices and systems illustrated in the figures are shown as having a multiplicity of components.
  • Various implementations of devices and/or systems, as described herein, may include fewer components and remain within the scope of the disclosure. Alternately, other implementations of devices and/or systems may include additional components, or various combinations of the described components, and remain within the scope of the disclosure.
  • the wearable device can be worn on any part of body as long as it fits to the shape, for example, earlobe, nostril, arm and fingertip. According to [11] "For instance, at 10 kHz the impedance modulus of the 300 mg/dl sample in the first animal was 74.0 ⁇ , while in the second animal it was 71.3 ⁇ .
  • implementation of the techniques disclosed herein may allow realisation of significant technical benefits. For instance, a true non-invasive solution implementing multiple sensors may obviate the requirement hitherto prevalent in the field of requiring invasive monitoring.
  • Known CGMS systems typically have a limited life cycle of between three and seven days.
  • Wearable devices implementing the techniques described herein may have lifetimes of between around 12 and 18 months, depending on the precise CMOS IC lifetime. Use of a CMOS, along with the described light source and sensing components may lead to a greatly-enhanced product life.
  • a number of known CGMS systems require a significant sensor warm up time of between around 2 and 10 hours. Wearable devices implementing the techniques described herein may not require any warm up time.
  • CGMS sensors are prone to bio-fouling.
  • the disclosed NI-CGMS device is not prone to bio-fouling as it is non-invasive
  • Varying skin tone and skin thickness for multiple individuals using the same non- invasive device requires tedious and multiple calibration cycles with blood glucose meter device.
  • radio frequency module e.g. utilising mm wave technology
  • skin tone and skin thickness is taken into account in the algorithm, hence simple calibration as shown in Figure 13 can be achieved.
  • a suitable calibration reference point may be chosen automatically when the user uses the NI-CGMS device.
  • the machine learning algorithm can automatically sense variations in the accuracy of the light spectroscopy sensor's output and pick a new calibration point in the event that the skin parameters have changed.
  • hypoglycaemic events The described light spectroscopy and dielectric spectroscopy techniques, with the help of bio-impedance, heart rate, temperature, and accelerometer measurements can precisely predict/detect hypoglycaemic events.
  • Some known CGMS sensors have a lag time of between around 5-15 minutes to report blood glucose concentration since these sensors measure interstitial fluids (ISF) glucose concentration and require three or more stage digital filtering.
  • the techniques described herein may allow real time or near real time continuous glucose measurement with minimum lag, which may be at most of the order of a few seconds to one minute because of sensor signal post processing since blood glucose is measured non-invasively.
  • the above-described wearable device does not require multi stage filtering; the device is not limited to dealing with Nano ampere sensor currents as compared to some known CGMS sensors.
  • CGMS sensors have major portability issues.
  • a separate wireless transceiver may be required to be attached to the body (e.g. in the abdomen area) which is connected to in-vivo enzymatic sensors.
  • a separate tube carrying ISF fluid needs to be attached to the body (e.g. in the abdomen area)
  • waist/abdomen area and connected to external sensor for glucose readings.
  • the inventors propose a wearable thin, small area, waterproof sensor as described above, with the attendant sensing and detecting techniques, which can be connected to a smart watch or similar communicating device.
  • Known non-invasive devices suffer from degradation of signal to noise ratio and sensitivity.
  • the signal-to-noise ratio can be increased by using methods that employs parallel monitoring using multiple methods and parameters.
  • Our system uses a multi-sensor approach and employs various parallel methods to maximize the signal to noise ratio.
  • the techniques described herein may allow a NI-CGMS to wirelessly link with artificial pancreas for automatic insulin injection.
  • the techniques use, for example, FMCW for dielectric spectroscopy and detecting blood glucose concentration.
  • Other modulation schemes, frequency bands could be used, such as CW, AM and PM.
  • the techniques may use frequency bands from 1- 300Ghz.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Artificial Intelligence (AREA)
  • Radiology & Medical Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Evolutionary Computation (AREA)
  • Fuzzy Systems (AREA)
  • Mathematical Physics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Signal Processing (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

L'invention concerne un appareil serveur (102) pour surveiller la glycémie chez un porteur (106) d'un dispositif portable (104) qui est configuré pour exécuter le premier mode de fonctionnement de surveillance de la glycémie d'une personne portant le dispositif à l'aide de données obtenues par un module de surveillance de la glycémie (124) à radio-fréquence dans le dispositif portable. L'appareil serveur est également configuré pour effectuer un second mode de fonctionnement de surveillance de la glycémie à l'aide de données obtenues par un module de surveillance de la glycémie par spectroscopie de lumière (126) dans le dispositif portable. L'appareil serveur effectue une comparaison de seuil entre une valeur de glycémie de référence pour la personne portant le dispositif et la valeur de glycémie (314) seuil. Un premier des premier mode de fonctionnement et second mode de fonctionnement est sélectionné en fonction de la comparaison de seuil.
PCT/SG2015/050454 2014-11-18 2015-11-18 Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés WO2016080911A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2015350582A AU2015350582A1 (en) 2014-11-18 2015-11-18 Server apparatus and wearable device for blood glucose monitoring and associated methods
SG11201704055YA SG11201704055YA (en) 2014-11-18 2015-11-18 Server apparatus and wearable device for blood glucose monitoring and associated methods
EP15860746.5A EP3220824A4 (fr) 2014-11-18 2015-11-18 Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés
JP2017526639A JP2017538474A (ja) 2014-11-18 2015-11-18 血糖モニタリングのためのサーバ装置およびウェアラブル・デバイス、ならびに関連する方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201407731T 2014-11-18
SG10201407731T 2014-11-18

Publications (1)

Publication Number Publication Date
WO2016080911A1 true WO2016080911A1 (fr) 2016-05-26

Family

ID=56014299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2015/050454 WO2016080911A1 (fr) 2014-11-18 2015-11-18 Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés

Country Status (5)

Country Link
EP (1) EP3220824A4 (fr)
JP (1) JP2017538474A (fr)
AU (1) AU2015350582A1 (fr)
SG (1) SG11201704055YA (fr)
WO (1) WO2016080911A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
WO2017218878A1 (fr) * 2016-06-17 2017-12-21 The Board Of Trustees Of The University Of Illinois Systèmes microfluidiques souples et portables capables de capturer, stocker et détecter des fluides biologiques
CN108078570A (zh) * 2016-11-21 2018-05-29 南通九诺医疗科技有限公司 一种内置加速度传感器的动态血糖监测电路及其控制方法
US10035010B1 (en) 2017-09-28 2018-07-31 Carydean Enterprises LLC Systems and methods for drug delivery
US10057395B1 (en) 2017-08-27 2018-08-21 Carydean Enterprises LLC Case for a mobile electronic device
WO2019084537A1 (fr) * 2017-10-29 2019-05-02 Rourk Christopher J Circuits de porte de transport d'électrons et procédés de fabrication, de fonctionnement et d'utilisation
KR20190046565A (ko) * 2017-10-26 2019-05-07 (주)오상헬스케어 검체의 농도 측정 방법 및 장치
CN109770877A (zh) * 2017-11-14 2019-05-21 三星电子株式会社 控制感测装置的系统及方法及传感器系统
WO2020116756A1 (fr) * 2018-12-04 2020-06-11 Samsung Electronics Co., Ltd. Procédé de guidage de mesure de signal biologique dans un dispositif portable
CN111372506A (zh) * 2017-09-18 2020-07-03 首尔国立大学医院 使用可穿戴设备预测甲状腺毒症的系统和计算机程序
EP3714789A1 (fr) * 2019-03-25 2020-09-30 Samsung Electronics Co., Ltd. Appareil et procédé de soins de santé
US10817780B2 (en) 2017-10-29 2020-10-27 Christopher J. Rourk Electron transport gate circuits and methods of manufacture, operation and use
CN111954492A (zh) * 2018-03-22 2020-11-17 阿诺·查斯 材料收集设备
CN112450919A (zh) * 2020-11-11 2021-03-09 云南省第一人民医院 一种用于评估2型糖尿病患者夜间低血糖的血糖监测装置
USD928835S1 (en) 2018-12-07 2021-08-24 Avon Kuo Display screen or portion thereof with an animated graphical user interface
US11197612B2 (en) 2017-10-05 2021-12-14 American University Of Beirut Non-invasive biological, chemical markers and tracers monitoring device in blood including glucose monitoring using adaptive RF circuits and antenna design
GB2604346A (en) * 2021-03-01 2022-09-07 Medical Wireless Sensing Ltd Dual-mode biosensor
WO2022184633A1 (fr) * 2021-03-01 2022-09-09 Medical Wireless Sensing Ltd. Biocapteur à double mode
GB2610612A (en) * 2021-09-10 2023-03-15 Medical Wireless Sensing Ltd Biosensor
US11642045B1 (en) 2012-09-25 2023-05-09 Micro Mobio Corporation Personal health and environmental monitoring device and method
WO2023201010A1 (fr) * 2022-04-14 2023-10-19 Academia Sinica Prédiction de glycémie non invasive par système d'apprentissage de déduction
US11998307B2 (en) 2018-03-22 2024-06-04 Arnold Chase Continuous blood glucose monitor

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210017659A (ko) * 2019-08-09 2021-02-17 주식회사 아이센스 연속 혈당 측정 시스템의 통신 연결 방법
KR20210092577A (ko) 2020-01-16 2021-07-26 삼성전자주식회사 성분 분석 장치 및 방법과 임피던스 측정 장치
KR102325887B1 (ko) * 2020-09-22 2021-11-15 큐어스트림(주) 혈당 조절 시스템 및 방법
WO2022254462A1 (fr) * 2021-06-04 2022-12-08 Sheth Mahesh Manohar Dispositif de mesure non invasive et indolore du glucose et procédé associé
WO2023113505A1 (fr) * 2021-12-17 2023-06-22 주식회사 에스비솔루션 Montre connectée détectant des informations biométriques sur la base d'une détection de permittivité
ES2948213A1 (es) * 2022-02-11 2023-09-06 Smarthealth S L Dispositivo portable y método para la estimación no invasiva del nivel de valores fisiológicos

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077260A1 (fr) * 2004-02-12 2005-08-25 Biopeak Corporation Procede et appareil non invasifs permettant de determiner un parametre physiologique
WO2007053963A1 (fr) * 2005-11-10 2007-05-18 Solianis Holding Ag Dispositif permettant de determiner le niveau de glucose dans un tissu corporel
WO2009152624A1 (fr) * 2008-06-18 2009-12-23 Solianis Holding Ag Dispositif et procédé pour déterminer au moins un paramètre de caractérisation de tissus corporels multicouches
WO2010062898A1 (fr) * 2008-11-26 2010-06-03 University Of Virginia Patent Foundation Procédé, système, et produit de programme d'ordinateur pour suivre une variabilité glycémique dans le diabète

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077260A1 (fr) * 2004-02-12 2005-08-25 Biopeak Corporation Procede et appareil non invasifs permettant de determiner un parametre physiologique
WO2007053963A1 (fr) * 2005-11-10 2007-05-18 Solianis Holding Ag Dispositif permettant de determiner le niveau de glucose dans un tissu corporel
WO2009152624A1 (fr) * 2008-06-18 2009-12-23 Solianis Holding Ag Dispositif et procédé pour déterminer au moins un paramètre de caractérisation de tissus corporels multicouches
WO2010062898A1 (fr) * 2008-11-26 2010-06-03 University Of Virginia Patent Foundation Procédé, système, et produit de programme d'ordinateur pour suivre une variabilité glycémique dans le diabète

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3220824A4 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11642045B1 (en) 2012-09-25 2023-05-09 Micro Mobio Corporation Personal health and environmental monitoring device and method
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9448164B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9453794B2 (en) 2014-09-29 2016-09-27 Zyomed Corp. Systems and methods for blood glucose and other analyte detection and measurement using collision computing
US9442065B2 (en) 2014-09-29 2016-09-13 Zyomed Corp. Systems and methods for synthesis of zyotons for use in collision computing for noninvasive blood glucose and other measurements
US9459203B2 (en) 2014-09-29 2016-10-04 Zyomed, Corp. Systems and methods for generating and using projector curve sets for universal calibration for noninvasive blood glucose and other measurements
US9459202B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for collision computing for detection and noninvasive measurement of blood glucose and other substances and events
US9448165B2 (en) 2014-09-29 2016-09-20 Zyomed Corp. Systems and methods for control of illumination or radiation collection for blood glucose and other analyte detection and measurement using collision computing
US9610018B2 (en) 2014-09-29 2017-04-04 Zyomed Corp. Systems and methods for measurement of heart rate and other heart-related characteristics from photoplethysmographic (PPG) signals using collision computing
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
WO2017218878A1 (fr) * 2016-06-17 2017-12-21 The Board Of Trustees Of The University Of Illinois Systèmes microfluidiques souples et portables capables de capturer, stocker et détecter des fluides biologiques
US20180064377A1 (en) * 2016-06-17 2018-03-08 The Board Of Trustees Of The University Of Illinois Soft, wearable microfluidic systems capable of capture, storage, and sensing of biofluids
US11596329B2 (en) 2016-06-17 2023-03-07 The Board Of Trustees Of The University Of Illinois Soft, wearable microfluidic systems capable of capture, storage and sensing of biofluids
US10653342B2 (en) 2016-06-17 2020-05-19 The Board Of Trustees Of The University Of Illinois Soft, wearable microfluidic systems capable of capture, storage, and sensing of biofluids
CN108078570A (zh) * 2016-11-21 2018-05-29 南通九诺医疗科技有限公司 一种内置加速度传感器的动态血糖监测电路及其控制方法
US10057395B1 (en) 2017-08-27 2018-08-21 Carydean Enterprises LLC Case for a mobile electronic device
CN111372506A (zh) * 2017-09-18 2020-07-03 首尔国立大学医院 使用可穿戴设备预测甲状腺毒症的系统和计算机程序
US11571170B2 (en) 2017-09-18 2023-02-07 Thyroscope Inc. Method for providing alert of potential thyroid abnormality
EP3685735A4 (fr) * 2017-09-18 2021-10-13 Thyroscope Inc. Système et programme informatique pour prédire l'hyperthyroïdie à l'aide d'un dispositif vestimentaire
US11903743B2 (en) 2017-09-18 2024-02-20 Thyroscope Inc. Method for providing alert of potential thyroid abnormality
US10035010B1 (en) 2017-09-28 2018-07-31 Carydean Enterprises LLC Systems and methods for drug delivery
US11197612B2 (en) 2017-10-05 2021-12-14 American University Of Beirut Non-invasive biological, chemical markers and tracers monitoring device in blood including glucose monitoring using adaptive RF circuits and antenna design
KR20190046565A (ko) * 2017-10-26 2019-05-07 (주)오상헬스케어 검체의 농도 측정 방법 및 장치
KR102016393B1 (ko) 2017-10-26 2019-09-10 (주)오상헬스케어 검체의 농도 측정 방법 및 장치
WO2019084537A1 (fr) * 2017-10-29 2019-05-02 Rourk Christopher J Circuits de porte de transport d'électrons et procédés de fabrication, de fonctionnement et d'utilisation
US10817780B2 (en) 2017-10-29 2020-10-27 Christopher J. Rourk Electron transport gate circuits and methods of manufacture, operation and use
CN109770877A (zh) * 2017-11-14 2019-05-21 三星电子株式会社 控制感测装置的系统及方法及传感器系统
CN111954492A (zh) * 2018-03-22 2020-11-17 阿诺·查斯 材料收集设备
US11998307B2 (en) 2018-03-22 2024-06-04 Arnold Chase Continuous blood glucose monitor
US11950896B2 (en) 2018-03-22 2024-04-09 Arnold Chase Blood glucose tracking system
US11510582B2 (en) 2018-12-04 2022-11-29 Samsung Electronics Co., Ltd. Method for guiding measurement of biological signal in wearable device
WO2020116756A1 (fr) * 2018-12-04 2020-06-11 Samsung Electronics Co., Ltd. Procédé de guidage de mesure de signal biologique dans un dispositif portable
USD928835S1 (en) 2018-12-07 2021-08-24 Avon Kuo Display screen or portion thereof with an animated graphical user interface
EP3714789A1 (fr) * 2019-03-25 2020-09-30 Samsung Electronics Co., Ltd. Appareil et procédé de soins de santé
CN112450919B (zh) * 2020-11-11 2022-11-04 云南省第一人民医院 一种用于评估2型糖尿病患者夜间低血糖的血糖监测装置
CN112450919A (zh) * 2020-11-11 2021-03-09 云南省第一人民医院 一种用于评估2型糖尿病患者夜间低血糖的血糖监测装置
WO2022184623A1 (fr) * 2021-03-01 2022-09-09 Medical Wireless Sensing Ltd. Biocapteur à double mode
WO2022184633A1 (fr) * 2021-03-01 2022-09-09 Medical Wireless Sensing Ltd. Biocapteur à double mode
GB2604346A (en) * 2021-03-01 2022-09-07 Medical Wireless Sensing Ltd Dual-mode biosensor
WO2023036956A1 (fr) * 2021-09-10 2023-03-16 Medical Wireless Sensing Ltd. Biocapteur
GB2610612A (en) * 2021-09-10 2023-03-15 Medical Wireless Sensing Ltd Biosensor
WO2023201010A1 (fr) * 2022-04-14 2023-10-19 Academia Sinica Prédiction de glycémie non invasive par système d'apprentissage de déduction

Also Published As

Publication number Publication date
EP3220824A4 (fr) 2018-07-04
EP3220824A1 (fr) 2017-09-27
SG11201704055YA (en) 2017-06-29
JP2017538474A (ja) 2017-12-28
AU2015350582A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
EP3220824A1 (fr) Appareil serveur et dispositif portable de surveillance de la glycémie et procédés associés
EP3742960B1 (fr) Systèmes, dispositifs et procédés pour compenser des effets de température sur des capteurs
EP3389492B1 (fr) Système de détection non invasif
JP3242346U (ja) 生理学的測定値の非侵襲的監視のための装置、およびシステム
Abd Salam et al. The evolution of non-invasive blood glucose monitoring system for personal application
US20210161423A1 (en) Apparatus and Method for Optical Spectroscopy and Bioimpedance Spectroscopy using a Mobile Device Case to Gather Physiological Information
Freer et al. Feasibility study for non-invasive blood glucose monitoring
Losoya-Leal et al. State of the art and new perspectives in non-invasive glucose sensors
Jain et al. Everything you wanted to know about noninvasive glucose measurement and control
US10092225B2 (en) Non-invasive system and method for measuring blood glucose in the human body utilizing a modified ceramic coaxial resonator
US20220095968A1 (en) Systems, devices, and methods to compensate for temperature effects on sensors
Yunos et al. Non-invasive glucose monitoring devices: A review
US20200352482A1 (en) Device for non-invasively measuring glucose concentration
Mhatre et al. Human body model with blood flow properties for non-invasive blood glucose measurement
Choi Recent developments in minimally and truly non-invasive blood glucose monitoring techniques
CN107928681B (zh) 一种基于耳垂血液层的微波能量谱无创血糖浓度检测法
Bakkali et al. First microwave tomography approach towards a truly noninvasive, pain-free and wearable blood glucose monitoring device
Sutradhar et al. A review of non-invasive electromagnetic blood glucose monitoring techniques
Amaral et al. Effects of glucose in blood and skin impedance spectroscopy
Singh et al. A Defected Ground Comb Shape Microwave Sensor for Non Invasive Measurement of Blood Glucose
Hanna et al. Electromagnetic based devices for non-invasive glucose monitoring
KR20210091559A (ko) 심전도 웨어러블 디바이스를 활용한 혈압과 혈당 측정 방법 및 장치
Sindhuja et al. Diabetic technology in India: Status, barriers, and future prospects
Venkatesan et al. Investigation and Validation of Non Invasive Blood Glucose Measurement
Shanmugapriya et al. Non-Invasive Optical Glucose Monitoring Using Laser Spectroscopy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15860746

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017526639

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11201704055Y

Country of ref document: SG

REEP Request for entry into the european phase

Ref document number: 2015860746

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015350582

Country of ref document: AU

Date of ref document: 20151118

Kind code of ref document: A